According to an article on the PharmaTimes website, Inhaled Insulin marketed as Exubera® is being pulled from the market for commercial reasons.
Despite some heavy promotional activity the product has failed to make any impact in the diabetes market. According to PharmaTimes, this decision will cost the manufacturer $2.8 billion in terms of current inventory stock, fixed assets and exit costs in addition to the $1.3 billion already paid back in 2006 to ensure sole marketing rights to the drug.
Action: Patients who are currently being treated with inhaled insulin will need to be moved to an alternative treatment within the next three months.
|« October MTRAC reviews||Safety review of glitazones complete »|